In development for several years, PORTIN is now being deployed as a single point of reference for all genotype and phenotype data at Bayer's research sites.
The analytics firm formerly known as Quintiles IMS will offer researchers secure access to Genomics England's de-identified databases in pursuit of precision medicine.
The financing round will support uBiome's ongoing efforts to commercialize its clinical microbiome analysis, sexually-transmitted disease, and gut wellness tests.
Vertex Pharmaceuticals has invested £10.5 million in the British analytics company as the companies launch a multiyear R&D partnership seeking novel drug targets.
Elucidata, which makes software to support drug discovery, recently released a metabolomics analysis platform that includes machine learning technology.
The UK-based Dementia Discovery Fund is investing $1.3M in Immuneering's drug-discovery technology in search of new molecular entities for treating Alzheimer's.
With the Series B funding, Sytenkabio will consolidate its headquarters in Seoul, validate its technology, and look to expand into international markets.
